Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S510000, C514S640000, C514S680000, C514S718000, C544S294000, C548S215000, C560S036000, C560S041000, C560S300000, C564S265000, C568S326000, C568S329000, C568S633000
Reexamination Certificate
active
06949557
ABSTRACT:
The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.
REFERENCES:
patent: 6372785 (2002-04-01), Huang
Duffault et al., Synthetic Communications, 28(13), 2467-2481, 1998.
Morier-Teissier, E., et al. “Synthesis and Antitumor Properties of an Anthraquinone Bisubstituted by the Copper . . . Gly-Gly-L-His”J. of Medicinal Chemistry, vol. 36, No. 15, p. 2084-2090, (1993).
Denny, W.A. “DNA-intercalating ligands as anti-cancer drugs: prospects for future design”Anti-Cancer Drug Design, vol. 4, p. 241-263, (1989).
Faulds, D., et al. “Mitoxantrone”Drugs, vol. 41, No. 3, p. 400-449, (1991).
Luft, B.J. “Mitoxantrone-induced Bradycardia”Annals of Internal Medicine, vol. 126, No. 5, p. 409, (1997).
Bailly, J.D., et al. “Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis”Leukemia, vol. 11, p. 1523-1532, (1997).
Krapcho, A.P, et al. “Synthesis and Antitumor Evaluation of 2,5-Disubstituted-Indazolo[4,3-gh] isoquinolin . . . ”J. of Medicinal Chemistry, vol. 41, No. 27, p. 5429-5444, (1998).
Lown, J.W., et al. “Characteristics of the Binding of the Anticancer Agents Mitoxantrone and Ametantrone and Related...Acids”Biochemistry, vol. 24, p. 4028-4035, (1985).
Zunino, F., et al. “DNA topoisomerase II as the primary target of anti-tumor anthracyclines”Anti-Cancer Drug Design, vol. 5, p. 307-317, (1990).
Huang, H-S, et al. “Studies on Anthracenes. 1. Human Telomerase Inhibition and Lipid Peroxidation of 9-Acyloxy. . .Derivatives”Chem. Pharm. Bull.,vol. 49, No. 8, p. 969-973, (2001).
Perry, P.J., et al. “Human Telomerase Inhibition by Regioisomeric Disubstituted Amidoanthracene-9, 10-diones”J. of Medicinal Chemistry, vol. 41, No. 24, p. 4873-4884, (1998).
Zagotto, G., et al. “New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents”II Farmaco, vol. 55, p. 1-5, (2000).
Johnson, R.K., et al. “Experimental Antitumor Activity of Aminoanthraquinones”Cancer Treatment Reports, vol. 63, No. 3, p. 425-439, (1979).
Banerjee Asish Kumar
Desiraju Gautam
Dutta Sankar Kumar
Giri Venkatachalam Sesha
Jaggi Manu
Dabur Research Foundation
Ladas & Parry LLP
LandOfFree
Hydroanthracene based compounds as anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroanthracene based compounds as anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroanthracene based compounds as anticancer agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406209